Generic Product News

Published Online: Tuesday, August 6, 2013
Follow Pharmacy_Times:

Methylphenidate Hydrochloride Tablets

Marketed by: Caraco Pharmaceutical Laboratories
Compare to: Ritalin (Novartis)
Indication: Caraco Pharmaceutical Laboratories, a division of Sun Pharmaceutical Industries Limited, has released methylphenidate hydrochloride, a generic equivalent to Novartis’ Ritalin. It is indicated for the treatment of attention deficit disorder symptoms, including moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. It is contraindicated in patients with marked anxiety, tension, and agitation, in patients with motor tics or a family history or diagnosis of Tourette’s syndrome, and in patients with glaucoma.
Dosage Form: Tablets: 5, 10, and 20 mg
For More Information:

My Way LevonorgestreL Tablets, 1.5 Mg
Marketed by: GAVIS Pharmaceuticals
Compare to: Plan B (Teva Pharmaceuticals)
Indication: My Way levonorgestrel tablets, 1.5 mg, was launched by GAVIS Pharmaceuticals. My Way levonorgestrel tablets are a generic equivalent to Teva’s Plan B, and are indicated to prevent pregnancy after known or suspected contraceptive failure or unprotected intercourse. Tablets should be taken orally within 72 hours of unprotected intercourse or contraceptive failure. Tablets are more effective if taken earlier within the 72-hour window.
Dosage Form: Tablets: 1.5 mg
For More Information:

Diphenhydramine Hydrochloride Injection, USP
Marketed by: BD Rx Inc
Indication: BD has released Diphenhydramine Hydrochloride Injection, USP, to launch BD Simplist, its line of prefilled generic injectable medications. It is indicated for amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled, and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated.
Dosage Form: Injection: 50 mg/mL
For More Information:

Calcitriol Soft Gel Capsules
Marketed by: Heritage Pharmaceuticals Inc
Compare to: Rocaltrol (Hoffmann-La Roche)
Indication: Heritage Pharmaceuticals Inc announces the availability of calcitriol soft gel capsules, an AB-rated generic equivalent to Hoffmann-La Roche’s synthetic vitamin D product Rocaltrol. It is indicated for the treatment of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure who are not yet on dialysis. It is also indicated for the management of hypocalcemia in patients who are undergoing dialysis.
Dosage Form: Capsules: 0.25 and 0.5 mcg
For More Information:

Related Articles
Today Reps. Doug Collins (R-Ga.) and Dave Loebsack (D-Iowa) introduced H.R. 5815, The Generic Drug Pricing Fairness Act, which creates greater transparency in how pharmacy benefit managers reimburse pharmacies for generic prescription drugs under Medicare Part D, and the Federal Employees Health Benefits Program. The National Community Pharmacists Association endorsed the bill, which goes further than legislation the same two Congressmen introduced earlier year that has the same remedies, but only applied to Medicare Part D.
“GPhA applauds FDA for taking helpful steps to address, and hopefully limit, scenarios in which some brand drug companies misuse Risk Evaluation and Mitigation Strategies programs to thwart competition from more affordable generic drugs. The ongoing abuse of REMS and REMS-like programs costs the American health system and its patients $5.4 billion annually, according to a study conducted by Matrix Global Advisors. Interestingly, as the United States market readies for biosimilars, this same study identifies $140 million in lost savings that would occur for every $1 billion in biologics sales.
Novartis announced its analysis of fingolimod in primary-progressive multiple sclerosis (PPMS) resulted in no significant difference from placebo, according to its phase 3 INFORMS study.
Latest Issues